Tony Berberabe, MPH

The number of cancer survivors in the United States is approaching 14 million, but that good news also means more attention must be paid to quality-of-life concerns for these individuals, as well as any long-term after effects of treatment.

As more cancer therapies move out of the infusion room and into the patient's home, ensuring that patients take these medications as prescribed poses an ongoing, multifaceted challenge for today's oncology practitioner.

Dermatologic adverse events (AEs) associated with anticancer therapies can be complex and are best managed with a proactive and holistic approach-one that takes into account not only the physical demands of the regimen itself, but also the many challenges that patients often face involving treatment adherence, quality of life, and psychosocial concerns.

Head and neck cancer patients who participated in a swallow preservation protocol (SPP) were less likely to suffer from the detrimental effects associated with dysphagia, a common complication associated with radiation therapy (RT) and chemoradiation therapy (CRT).

Many patients being treated with mTOR inhibitors experience dermatologic-related adverse events.